| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.5 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.096 | 0.6 |